INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial

MLA

Nesri Padayatchi, et al. “INSTIs for the Management of HIV-Associated TB (INSIGHT Study): A Phase 2b Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate for the Treatment of HIV-1 Infection in Patients with Drug-Susceptible Tuberculosis on a Rifampicin-Based Treatment Regimen: A Phase 2b Open-Label Randomised Controlled Trial.” BMJ Open, vol. 12, no. 11, Nov. 2022. EBSCOhost, https://doi.org/10.1136/bmjopen-2022-067765.

APA

Nesri Padayatchi, Kogieleum Naidoo, Anushka Naidoo, Kelly E Dooley, Nonhlanhla Yende-Zuma, Rubeshan Perumal, Gillian Dorse, Resha Boodhram, & Emmanuella Chinonso Osuala. (2022). INSTIs for the management of HIV-associated TB (INSIGHT study): a phase 2b study to evaluate the efficacy, safety and pharmacokinetics of a combination of bictegravir, emtricitabine and tenofovir alafenamide fumarate for the treatment of HIV-1 infection in patients with drug-susceptible tuberculosis on a rifampicin-based treatment regimen: a phase 2b open-label randomised controlled trial. BMJ Open, 12(11). https://doi.org/10.1136/bmjopen-2022-067765

Chicago

Nesri Padayatchi, Kogieleum Naidoo, Anushka Naidoo, Kelly E Dooley, Nonhlanhla Yende-Zuma, Rubeshan Perumal, Gillian Dorse, Resha Boodhram, and Emmanuella Chinonso Osuala. 2022. “INSTIs for the Management of HIV-Associated TB (INSIGHT Study): A Phase 2b Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide Fumarate for the Treatment of HIV-1 Infection in Patients with Drug-Susceptible Tuberculosis on a Rifampicin-Based Treatment Regimen: A Phase 2b Open-Label Randomised Controlled Trial.” BMJ Open 12 (11). doi:10.1136/bmjopen-2022-067765.